DOJ’s “New Madison” approach to antitrust and intellectual property law dictates that antitrust should stay out of disputes over patents, even when market power...
Federal antitrust enforcement has been robust and effective in promoting prescription drug market competition and thereby enhancing consumer welfare. Antitrust enforcement in itself, however,...
Although not the sole cause of high prescription drug costs, abusive practices that distort competition contribute to the problem. Too many companies exclude competition...
Chicago Booth alumnus and retired health care consultant David W. Ennis responds to ProMarket’s recent coverage on antitrust and the US health care system....
The unraveling of the T-Mobile/Sprint remedy continues a trend of failed merger consent decrees. One solution, proposed by two antitrust scholars, is to ban...
Big Tech firms are facing the biggest wave of antitrust legislation in their history. Academic literature reveals the complexity of possible consequences of the...